The rubber processor Semperit has announced record numbers for the first nine months of 2020. The company with its headquarters in Wimpassing in the Schwarzatale (Neunkirchen district) is benefiting from the hygiene requirements in the pandemic.
The forecasts have already been raised several times for 2020 as a whole. The Management Board is currently assuming that the result could be maintained or exceeded again in 2021. The reason for this is of all things the long-standing problem child, the medical division. This is about medical protective gloves, which experienced an unexpected surge in demand in the coronavirus pandemic.
The group spoke on Thursday of a special boom in medical products. Semperit produces medical gloves (surgical gloves, examination gloves) in Austria (Wimpassing) and Malaysia. Until the outbreak of the coronavirus crisis, the division should be sold in a timely manner – more on this in Semperit parts with the medical business (noe.ORF.at; January 28, 2020). The fundamental decision to sell is still being held. Today it said in the quarterly announcement that the medical business would in any case continue until mid-2021.
Due to the current development, the group also sees itself in a position to early repay the hybrid capital injected by the core shareholder B&C at the end of 2017 – in the next six months. At that time 150 million euros were made available, of which 130 million euros were drawn.
Light and shadow in quarterly figures
In the first nine months of the year, group sales rose moderately by 0.8 percent to EUR 657.2 million. There was an opposite development between the two branches medicine (plus 27.5 percent) and industry (minus 13.4 percent). The sharp rise in medicine has more than compensated for the decline in industry due to the global recession. According to the group, restructuring also had an impact on earnings.
The EBITDA (earnings before interest, taxes, depreciation and amortization) had almost doubled to 118.5 million euros by September. In the medical division alone, this value was EUR 67.3 million in the first three quarters of 2020, compared to EUR 5.6 million in the first three quarters of 2019. The EBIT in the group improved to EUR 159.5 million. In the same period of the previous year, there had been a loss of EUR 13.7 million in the group – mainly due to the previous year’s high depreciation-related losses in the medical division. For the year as a whole, the Management Board sees the group’s EBIT at 230 and 255 million euros this year.